{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:56Z","timestamp":1791396296383,"version":"4.3.3"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Proteasome 26S subunit, ATPase gene (PSMC) family members play a critical role in regulating protein degradation and are essential for tumor development. However, little is known about the integrative function and prognostic significance of the PSMC gene family members in lung cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> First, we assessed the expression and prognostic features of six PSMC family members in pan-cancer from The Cancer Genome Atlas (TCGA) dataset. Hence, by focusing on the relationship between PSMC genes and the prognostic, genomic, and tumor microenvironment features in lung adenocarcinoma (LUAD), a PSMC-based prognostic signature was established using consensus clustering and multiple machine learning algorithms, including the least absolute shrinkage and selection operator (LASSO) Cox regression, CoxBoost, and survival random forest analysis in TCGA and GSE72094. We then validated it in three independent cohorts from GEO and estimated the correlation between risk score and clinical features: genomic features (alterations, tumor mutation burden, and copy number variants), immune profiles (immune score, TIDE score, tumor-infiltrated immune cells, and immune checkpoints), sensitivity to chemotherapy (GDSC, GSE42127, and GSE14814), and immunotherapy (IMvigor210, GSE63557, and immunophenoscore). Twenty-one patients with LUAD were included in our local cohort, and tumor samples were submitted for evaluation of risk gene and PD-L1 expression.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Nearly all six PSMC genes were overexpressed in pan-cancer tumor tissues; however, in LUAD alone, they were all significantly correlated with overall survival. Notably, they all shared a positive association with increased TMB, TIDE score, expression of immune checkpoints (CD276 and PVR), and more M1 macrophages but decreased B-cell abundance. A PSMC-based prognostic signature was established based on five hub genes derived from the differential expression clusters of PSMC genes, and it was used to dichotomize LUAD patients into high- and low-risk groups according to the median risk score. The area under the curve (AUC) values for predicting survival at 1, 3, and 5 years in the training cohorts were all &amp;gt;.71, and the predictive accuracy was also robust and stable in the GSE72094, GSE31210, and GSE13213 datasets. The risk score was significantly correlated with advanced tumor, lymph node, and neoplasm disease stages as an independent risk factor for LUAD. Furthermore, the risk score shared a similar genomic and immune feature as PSMC genes, and high-risk tumors exhibited significant genomic and chromosomal instability, a higher TIDE score but lower immune score, and a decreased abundance of B and CD8<jats:sup>+<\/jats:sup> T cells. Finally, high-risk patients were suggested to be less sensitive to immunotherapy but had a higher possibility of responding to platinum-based chemotherapy. The LUAD samples from the local cohort supported the difference in the expression levels of these five hub genes between tumor and normal tissues and the correlation between the risk score and PD-L1 expression.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Overall, our results provide deep insight into PSMC genes in LUAD, especially the prognostic effect and related immune profile that may predict therapeutic responses.<\/jats:p>","DOI":"10.3389\/fgene.2022.1017866","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T12:48:51Z","timestamp":1673268531000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Hui","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e08153","DOI":"10.7554\/eLife.08153","article-title":"Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits","volume":"4","author":"Acosta-Alvear","year":"2015","journal-title":"eLife"},{"key":"B2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12935-021-01975-z","article-title":"A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)","volume":"21","author":"Al-Dherasi","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The multifaceted role of chromosomal instability in cancer and its microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: The cancer-immunity cycle","volume":"39","author":"Chen Daniel","year":"2013","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e10628","DOI":"10.7717\/peerj.10628","article-title":"Tumor microenvironment related novel signature predict lung adenocarcinoma survival","volume":"9","author":"Chen","year":"2021","journal-title":"PeerJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-021-00585-y","article-title":"PSMC2\/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma","volume":"7","author":"Duan","year":"","journal-title":"Cell. death Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"21325","DOI":"10.18632\/aging.203463","article-title":"Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1","volume":"13","author":"Duan","year":"","journal-title":"Aging-US"},{"key":"B12","doi-asserted-by":"publisher","first-page":"693062","DOI":"10.3389\/fimmu.2021.693062","article-title":"Clinical significance and immunologic landscape of a five-IL(R)-Based signature in lung adenocarcinoma","volume":"12","author":"Fan","year":"2021","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.657917","article-title":"PSMC5 promotes proliferation and metastasis of colorectal cancer by activating epithelial\u2013mesenchymal transition signaling and modulating immune infiltrating cells","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"eabi8800","DOI":"10.1126\/sciimmunol.abi8800","article-title":"Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer","volume":"6","author":"Horton","year":"2021","journal-title":"Sci. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1242\/jcs.177543","article-title":"Spatial control of Shoc2-scaffold-mediated ERK1\/2 signaling requires remodeling activity of the ATPase PSMC5","volume":"128","author":"Jang","year":"2015","journal-title":"J. Cell. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lungcan.2018.07.003","article-title":"The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base","volume":"123","author":"Jiao","year":"2018","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16144","DOI":"10.18632\/aging.203140","article-title":"A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma","volume":"13","author":"Jin","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tig.2020.09.005","article-title":"Trash talk: Mammalian proteasome regulation at the transcriptional level","volume":"37","author":"Kamber Kaya","year":"2020","journal-title":"Trends Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.18632\/aging.203345","article-title":"Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer","volume":"13","author":"Kao","year":"2021","journal-title":"Aging-US"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1038\/ncomms11612","article-title":"Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer","volume":"7","author":"Kaushik","year":"2016","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s42255-020-00316-0","article-title":"The hexosamine biosynthesis pathway is a targetable liability in KRAS\/LKB1 mutant lung cancer","volume":"2","author":"Kim","year":"2020","journal-title":"Nat. Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3389\/fimmu.2019.00954","article-title":"Targeting the complement pathway as a therapeutic strategy in lung cancer","volume":"10","author":"Kleczko","year":"2019","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"12298","DOI":"10.1038\/srep12298","article-title":"Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations","volume":"5","author":"Lesterhuis","year":"2015","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"W509-W514","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"749241","DOI":"10.3389\/fimmu.2022.749241","article-title":"The comprehensive analysis identified an autophagy signature for the prognosis and the immunotherapy efficiency prediction in lung adenocarcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"756340","DOI":"10.3389\/fcell.2021.756340","article-title":"Identification and validation of the pyroptosis-related molecular subtypes of lung adenocarcinoma by bioinformatics and machine learning","volume":"9","author":"Liu","year":"","journal-title":"Front. Cell. Dev. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41389-022-00386-7","article-title":"PSMC2 promotes the progression of gastric cancer via induction of RPS15A\/mTOR pathway","volume":"11","author":"Liu","year":"2022","journal-title":"Oncogenesis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"605754","DOI":"10.3389\/fmolb.2021.605754","article-title":"Upregulation of GNPNAT1 predicts poor prognosis and correlates with immune infiltration in lung adenocarcinoma","volume":"8","author":"Liu","year":"","journal-title":"Front. Mol. Biosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"607021","DOI":"10.3389\/fonc.2021.607021","article-title":"PSMC2 regulates cell cycle progression through the p21\/cyclin D1 pathway and predicts a poor prognosis in human hepatocellular carcinoma","volume":"11","author":"Liu","year":"","journal-title":"Front. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1200\/jco.2005.05.081","article-title":"The ubiquitin-proteasome pathway and its role in cancer","volume":"23","author":"Mani","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"n2363","DOI":"10.1136\/bmj.n2363","article-title":"Advances in systemic therapy for non-small cell lung cancer","volume":"375","author":"Miller","year":"2021","journal-title":"BMJ Clin. Res. ed)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"8483","DOI":"10.1038\/ncomms9483","article-title":"CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis","volume":"6","author":"Murayama","year":"2015","journal-title":"Nat. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.7150\/jca.27616","article-title":"PSMC2 is up-regulated in pancreatic cancer and promotes cancer cell proliferation and inhibits apoptosis","volume":"10","author":"Qin","year":"2019","journal-title":"J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e26476","DOI":"10.7554\/eLife.26476","article-title":"Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data","volume":"6","author":"Racle","year":"2017","journal-title":"eLife"},{"key":"B44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/1568009620666200226094000","article-title":"Updated review and perspective on 20S proteasome inhibitors in the treatment of lung cancer","volume":"20","author":"Rohondia","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"B47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.ccr-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1158\/1535-7163.MCT-17-0130","article-title":"CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for Bortezomib sensitivity in multiple myeloma","volume":"16","author":"Shi","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41598-022-06239-y","article-title":"Co-occurrence CDK4\/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer","volume":"12","author":"Sitthideatphaiboon","year":"2022","journal-title":"Sci. Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/ijms21082824","article-title":"The potential role of complement system in the progression of ovarian clear cell carcinoma inferred from the gene ontology-based immunofunctionome analysis","volume":"21","author":"Su","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"102990","DOI":"10.1016\/j.ebiom.2020.102990","article-title":"Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma","volume":"60","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet (London, Engl."},{"key":"B54","doi-asserted-by":"publisher","first-page":"935286","DOI":"10.3389\/fgene.2022.935286","article-title":"Evaluating the prognostic and therapeutic potentials of the proteasome 26S subunit, ATPase (PSMC) family of genes in lung adenocarcinoma: A database mining approach","volume":"13","author":"Ullah","year":"2022","journal-title":"Front. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lungcan.2011.01.029","article-title":"Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma","volume":"74","author":"Wagner","year":"2011","journal-title":"Lung Cancer"},{"key":"B56","first-page":"95","article-title":"Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41419-021-03960-w","article-title":"Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU)","volume":"12","author":"Wang","year":"2021","journal-title":"Cell. Death Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/15384101.2021.2021722","article-title":"PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K\/Akt pathway","volume":"21","author":"Wang","year":"2022","journal-title":"Cell. Cycle"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.21037\/atm-21-3301","article-title":"CCR2 and PTPRC are regulators of tumor microenvironment and potential prognostic biomarkers of lung adenocarcinoma","volume":"9","author":"Wei","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"645862","DOI":"10.3389\/fphar.2021.645862","article-title":"Catenin alpha-2 mutation changes the immune microenvironment in lung adenocarcinoma patients receiving immune checkpoint inhibitors","volume":"12","author":"Wen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1002\/ijc.32675","article-title":"PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer","volume":"146","author":"Wu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"759217","DOI":"10.3389\/fimmu.2021.759217","article-title":"Predictable roles of peripheral IgM memory B cells for the responses to anti-PD-1 monotherapy against advanced non-small cell lung cancer","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"BSR20181369","DOI":"10.1042\/BSR20181369","article-title":"Identification of candidate biomarkers associated with apoptosis in melanosis coli: GNG5, LPAR3, MAPK8, and PSMC6","volume":"39","author":"Xiaohang","year":"2018","journal-title":"Biosci. Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1158\/0008-5472.CAN-18-0689","article-title":"Tip: A web server for resolving tumor immunophenotype profiling","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41420-021-00727-2","article-title":"PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma","volume":"7","author":"Yang","year":"2021","journal-title":"Cell. Death Discov."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"W98-W102","DOI":"10.1093\/nar\/gkx247","article-title":"Gepia: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Zefang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1824641","DOI":"10.1080\/2162402X.2020.1824641","article-title":"Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma","volume":"9","author":"Zhang","year":"","journal-title":"OncoImmunology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9922185","DOI":"10.1155\/2021\/9922185","article-title":"The silence of PSMC6 inhibits cell growth and metastasis in lung adenocarcinoma","volume":"2021","author":"Zhang","year":"2021","journal-title":"BioMed Res. Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"806877","DOI":"10.3389\/fimmu.2022.806877","article-title":"CD8+ T cell-associated gene signature correlates with prognosis risk and immunotherapy response in patients with lung adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"BSR20201541","DOI":"10.1042\/BSR20201541","article-title":"C1QTNF6 regulates cell proliferation and apoptosis of NSCLC in vitro and in vivo","volume":"41","author":"Zhang","year":"2021","journal-title":"Biosci. Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1002\/jcp.29261","article-title":"PSMC6 promotes osteoblast apoptosis through inhibiting PI3K\/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model","volume":"235","author":"Zhang","year":"","journal-title":"J. Cell. Physiology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1186\/s12885-021-08957-4","article-title":"Prognostic value of SEC61G in lung adenocarcinoma: A comprehensive study based on bioinformatics and in vitro validation","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12935-020-01317-5","article-title":"A novel risk score system of immune genes associated with prognosis in endometrial cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Cancer Cell. Int."},{"key":"B76","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: An emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41419-021-03981-5","article-title":"PSMC2\/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration","volume":"12","author":"Zhu","year":"2021","journal-title":"Cell. death Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"909105","DOI":"10.3389\/fimmu.2022.909105","article-title":"Corrigendum: Clinical significance and immunometabolism landscapes of a novel recurrence-associated lipid metabolism signature in early-stage lung adenocarcinoma: A comprehensive analysis","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1017866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T12:48:57Z","timestamp":1673268537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1017866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":78,"alternative-id":["10.3389\/fgene.2022.1017866"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.1017866","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1017866"}}